Altered prostaglandin E1 dosage during extracorporeal membrane oxygenation in a newborn with ductal-dependent congenital heart disease.
We describe a neonate with ductal-dependent congenital heart disease on extracorporeal membrane oxygenation (ECMO) for persistent pulmonary hypertension, who required markedly high doses of prostaglandin E1 (PGE1) to maintain patency of the ductus arteriosus: The effects of ECMO on the pharmacokinetics of PGE1 are discussed.
Division of Cardiology, Carman Ann Adams Department of Pediatrics, Children's Hospital of Michigan, Wayne State University, 3901 Beaubien, Detroit, MI 48201, USA. dstone@dmc.org
D M
DM
Stone
D A C
DA
Frattarelli
S
S
Karthikeyan
Y R
YR
Johnson
K
K
Chintala
D000527:Alprostadil / Q000008:administration & dosage* / Q000378:metabolism; D004374:Ductus Arteriosus, Patent / Q000000981:diagnostic imaging; D015199:Extracorporeal Membrane Oxygenation; D005260:Female; D006330:Heart Defects, Congenital / Q000000981:diagnostic imaging / Q000628:therapy*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000151:congenital / Q000628:therapy; D007231:Infant, Newborn; D008471:Meconium Aspiration Syndrome / Q000628:therapy; D011666:Pulmonary Valve Stenosis / Q000628:therapy*; D014463:Ultrasonography; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000378:metabolism
D014665:Vasodilator Agents; D000527:Alprostadil